

F Stephen Hodi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/873230/f-stephen-hodi-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

59,457
citations

77
h-index

188
g-index

188
ext. papers

73,016
ext. citations

13.5
avg, IF

7.24
L-index

#	Paper	IF	Citations
176	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	9
175	Soluble PD-L1 as an early marker of progressive disease on nivolumab. 2022 , 10,		3
174	Reply to T. Olivier et al.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200209	2.2	
173	Mass cytometry staining for human bone marrow clinical samples.. <i>STAR Protocols</i> , 2022 , 3, 101163	1.4	0
172	Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials.. <i>STAR Protocols</i> , 2022 , 3, 101362	1.4	
171	SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis. <i>Cancer Research</i> , 2021 ,	10.1	4
170	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 2021 , 9,		2
169	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
168	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. <i>Haematologica</i> , 2021 , 106, 651-654	6.6	3
167	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. <i>Cancer Research Communications</i> , 2021 , 1, 30-40		2
166	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). <i>Melanoma Research</i> , 2021 , 31, 67-75	3.3	6
165	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021 , 10, 2627-2635	4.8	1
164	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021 , 23, 1961-1973	11.73	24
163	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9503-9503	2.2	49
162	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. <i>Npj Precision Oncology</i> , 2021 , 5, 62	9.8	6
161	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 1371-1380	12.9	18
160	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021 , 137, 1353-1364	2.2	11

159	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2209-2221	7.4	11
158	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 182-191	7.5	23
157	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021 , 11, 1524-1541	24.4	13
156	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021 , 137, 3212-3217	2.2	9
155	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021 , 100, 196-205	9.9	28
154	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021 , 9, 1202-1213	12.5	11
153	Long-term Overall Survival and Predictors in Anti-PD-1-naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021 , 44, 307-318	5	1
152	Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021 , 157, 493-510	7.5	4
151	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021 , 157, 391-402	7.5	2
150	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). <i>Clinical Cancer Research</i> , 2021 , 27, 5038-5048	12.9	1
149	Inactivation of Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. <i>Cancer Discovery</i> , 2020 , 10, 1296-1311	24.4	16
148	A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. <i>Nature Medicine</i> , 2020 , 26, 792-802	50.5	130
147	Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. <i>JCO Oncology Practice</i> , 2020 , 16, e933-e942	2.3	13
146	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. <i>Cancer</i> , 2020 , 126, 3758-3767	6.4	10
145	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020 , 182, 655-671. 50.2	50.2	85
144	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020 , 26, 5086-5091	12.9	11
143	Tumor Mutational Burden and Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2565-2572	12.9	71
142	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020 , 8, 1075-1084	12.5	21

141	Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells. <i>Journal of Biological Methods</i> , 2020 , 7, e131	1.4	4
140	Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	3
139	High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples. <i>STAR Protocols</i> , 2020 , 1, 100055	1.4	11
138	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. <i>Cancer</i> , 2020 , 126, 5274-5282	6.4	6
137	Integrated molecular drivers coordinate biological and clinical states in melanoma. <i>Nature Genetics</i> , 2020 , 52, 1373-1383	36.3	11
136	Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2020 , 26, 5631-5637	12.9	11
135	Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service 2020 , 8,		2
134	Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. <i>Cancer</i> , 2020 , 126, 5088-5097	6.4	11
133	Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020 , 38, 500-515.e3	24.3	75
132	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019 , 25, 6061-6072	12.9	33
131	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019 , 10, 4346	17.4	89
130	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
129	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 2174-2184	12.9	47
128	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 165-174	7.1	77
127	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019 , 7, 1214-1220	12.5	21
126	Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1331-1340	7.4	2
125	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019 , 5, 1411-1420	13.4	216
124	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. <i>Journal of Biological Methods</i> , 2019 , 6, e114	1.4	10

123	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
122	Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. <i>Nature Immunology</i> , 2019 , 20, 326-336	19.1	522
121	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. <i>Nature Communications</i> , 2019 , 10, 5157	17.4	29
120	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019 , 290, 9-22	20.5	95
119	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019 , 40, 17-65	27.2	209
118	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018 , 24, 4960-4967	12.9	142
117	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. <i>Cancer Immunology Research</i> , 2018 , 6, 630-635	12.5	40
116	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018 , 173, 624-633.e8	56.2	71
115	Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. <i>Genes and Diseases</i> , 2018 , 5, 46-48	6.6	27
114	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , 2018 , 19, e20-e32	21.7	63
113	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. <i>Cancer</i> , 2018 , 124, 1111-1121	6.4	46
112	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018 , 359, 801-806	33.3	562
111	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis 2018 , 6, 26		89
110	Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. <i>Science</i> , 2018 , 359, 1537-1542	33.3	196
109	PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. <i>British Journal of Haematology</i> , 2018 , 180, 752-755	4.5	14
108	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 173-182	13.4	467
107	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	227
106	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. <i>Cancer Immunology Research</i> , 2018 , 6, 1039-1045	12.5	42

105	Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells. <i>Cytotechnology</i> , 2018 , 70, 1-11	2.2	7
104	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018 , 50, 1271-1281	36.3	249
103	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730	59.2	659
102	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018 , 8, 196-215	24.4	228
101	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 850-858	2.2	184
100	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. <i>Melanoma Research</i> , 2018 , 28, 605-610	3.3	18
99	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018 , 175, 984-997.e24	56.2	477
98	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1480-1492	21.7	680
97	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1833-1844	7.4	30
96	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 3510-3519	12.9	86
95	Combination immunotherapy: a road map 2017 , 5, 16		228
94	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017 , 5, 312-318	12.5	259
93	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , 2017 , 18, e143-e152	21.7	1010
92	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 344-351	4	107
91	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017 , 123, 3285-3290	6.4	106
90	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. <i>Laboratory Investigation</i> , 2017 , 97, 207-216	5.9	13
89	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017 , 5, 480-492	12.5	196
88	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. <i>Clinical Cancer Research</i> , 2017 , 23, 4671-4679	12.9	84

87	Risk of Bias and Heterogeneity-Reply. <i>JAMA Oncology</i> , 2017 , 3, 858-859	13.4	
86	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 785-792	2.2	696
85	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017 , 5, 1133-1140	12.5	70
84	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017 , 171, 934-949	36.16	831
83	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. <i>Cancer Immunology Research</i> , 2017 , 5, 1046-1055	12.5	25
82	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series 2017 , 5, 66		27
81	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	16
80	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814	2.2	264
79	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
78	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017 , 23, 5737-5744	12.9	55
77	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 655-668	19.4	498
76	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. <i>JAMA Oncology</i> , 2017 , 3, 1511-1519	13.4	101
75	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
74	Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. <i>Oncotarget</i> , 2017 , 8, 6873-6882	3.3	32
73	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016 , 22, 6051-6060	12.9	292
72	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2016 , 2, 1607-1616	13.4	401
71	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 1558-1568	21.7	627
70	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016 , 4, 1038-1048	12.5	54

69	A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2016 , 5, 3041-3050	4.8	30
68	An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016 , 22, 5204-5210	12.9	11
67	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016 , 90, 638-47	9.9	353
66	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , 2016 , 48, 725-32	36.3	193
65	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 943-955	21.7	236
64	RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016 , 62, 138-45	7.5	117
63	Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 77-8	19.4	58
62	Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2016 , 4, 12-7	12.5	42
61	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016 , 76, 999-1008	10.1	297
60	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. <i>JAMA Oncology</i> , 2016 , 2, 518-22	13.4	95
59	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2016 , 4, 289-93	12.5	112
58	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1510-7	2.2	509
57	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. <i>Cancer Immunology Research</i> , 2016 , 4, 124-35	12.5	236
56	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. <i>JCI Insight</i> , 2016 , 1, e87415	9.9	89
55	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients 2016 , 4, 32		14
54	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. <i>Journal of Neuro-Oncology</i> , 2016 , 129, 389-393	4.8	4
53	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016 , 115, 252-60	8.7	51
52	RECIST 1.1-Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , 2016 , 62, 132-7	7.5	607

51	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9	27.4	666
50	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. <i>Clinical Cancer Research</i> , 2016 , 22, 3127-31	12.9	66
49	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4102-4109	2.2	400
48	Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 656-668	4.5	21
47	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2013-20	2.2	337
46	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2006-17	59.2	2001
45	Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. <i>Journal of Clinical Oncology</i> , 2015 , 33, e32-5	2.2	17
44	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2004-12	2.2	859
43	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1889-94	2.2	1425
42	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015 , 21, 3178-86	12.9	23
41	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. <i>European Journal of Radiology</i> , 2015 , 84, 1259-68	4.7	89
40	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015 , 7, 59	7.7	42
39	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015 , 3, 1185-92	12.5	168
38	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. <i>OncImmunology</i> , 2015 , 4, e1046028	7.2	166
37	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1389-403	3.5	70
36	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. <i>Cancer</i> , 2015 , 121, 4007-15	6.4	32
35	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. <i>Frontiers in Oncology</i> , 2015 , 5, 202	5.3	154
34	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study 2015 , 3, 3		63

33	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
32	Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. <i>Clinical Cancer Research</i> , 2015 , 21, 749-55	12.9	162
31	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015 , 3, 1158-64	12.5	205
30	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , 2015 , 16, e270-8	21.7	472
29	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2015 , 3, 986-91	12.5	17
28	Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma. <i>Cancer Immunology Research</i> , 2015 , 3, 59-67	12.5	3
27	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015 , 3, 855-63	12.5	53
26	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , 2015 , 3, 1308-15	12.5	96
25	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? 2014 , 2, 17		58
24	Hematology/Oncology Clinics of North America. Melanoma. Preface. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, xiii-xiv	3.1	2
23	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome 2014 , 2, 40		41
22	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1056-64	14.4	146
21	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014 , 515, 563-7	50.4	3354
20	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1744-53	27.4	259
19	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. <i>Cancer Immunology Research</i> , 2014 , 2, 643-54	12.5	190
18	Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9107-TPS9107	2.2	4
17	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3182-90	2.2	409
16	Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. <i>Cancer Imaging</i> , 2013 , 13, 626-32	5.6	23

15	The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. <i>Chinese Clinical Oncology</i> , 2013 , 2, 7	2.3	6
14	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 2443-54	59.2	8684
13	Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 655-65	7.4	17
12	The biologic importance of tumor-infiltrating lymphocytes. <i>Journal of Cutaneous Pathology</i> , 2010 , 37 Suppl 1, 48-53	1.7	31
11	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 711-23	59.2	10591
10	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. <i>Clinical Cancer Research</i> , 2009 , 15, 7412-20	12.9	2380
9	Major response to imatinib mesylate in KIT-mutated melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2046-51	2.2	373
8	Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 696-7		10
7	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3005-10	11.5	533
6	CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 557-61		143
5	Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. <i>Clinical Cancer Research</i> , 2008 , 14, 3896-905	12.9	27
4	Combinatorial cancer immunotherapy. <i>Advances in Immunology</i> , 2006 , 90, 341-68	5.6	38
3	Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 3398-403	11.5	95
2	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 6919-24	11.5	40
1	Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. <i>International Journal of Cancer</i> , 1988 , 41, 601-8	7.5	115